Order Article Reprints

Andrechak JC, Dooling LJ, Tobin MP, Zhang W, Hayes BH, Lee JY, Jin X, Irianto J, Discher DE. CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies. Cancers. 2022; 14(8):1930. https://doi.org/10.3390/cancers14081930

Andrechak, Jason C., Lawrence J. Dooling, Michael P. Tobin, William Zhang, Brandon H. Hayes, Justine Y. Lee, Xiaoling Jin, Jerome Irianto, and Dennis E. Discher. 2022. "CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies" Cancers 14, no. 8: 1930. https://doi.org/10.3390/cancers14081930

Andrechak, J. C., Dooling, L. J., Tobin, M. P., Zhang, W., Hayes, B. H., Lee, J. Y., Jin, X., Irianto, J., & Discher, D. E. (2022). CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies. Cancers, 14(8), 1930. https://doi.org/10.3390/cancers14081930